Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ABBV-8736 in adults with moderate to severe Crohn's disease
NL-OMON58861Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of ABBV-8736 in Crohn's disease, sponsored by AbbVie Inc. Primary endpoint: Endoscopic remission at Week 12. Started Jan 2025; status: recruiting.
02
Drugs
ABBV-8736
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON58861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58861.